Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2023-12-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) for Cytogen Co., Ltd. It details the meeting date, location, agenda items (appointment of directors, amendment of articles of incorporation), and voting procedures (including electronic voting). This document is a standard proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their votes, which fits the definition of a Proxy Solicitation & Information Statement.
2023-12-11 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of a new outside director (채광석) for the company Cytogen. This type of disclosure regarding changes in board composition falls under the 'Board/Management Information' category.
2023-12-11 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the resignation of an outside director (사외이사). It details the specific individual, the date of resignation, and the reason for the change. This falls under the category of announcements regarding changes in the company's board of directors or senior management.
2023-12-11 Korean
[기재정정]주주총회소집결의(임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from Cytogen regarding the rescheduling of an Extraordinary General Meeting (EGM). It details the change in the meeting date and provides information about the agenda (director appointment). Since this is a formal notice of a shareholder meeting and its procedural details, it falls under the category of Proxy Solicitation & Information Statement (PSI) as it relates to the solicitation of shareholder participation and meeting logistics.
2023-12-06 Korean
전환청구권행사(제3회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (전환사채) issued by Cytogen. It details the number of shares to be issued, the conversion price, and the remaining balance of the convertible bonds. This type of corporate action, involving the conversion of debt into equity, falls under capital structure changes and share issuance, which is best classified as Share Issue/Capital Change (SHA).
2023-12-01 Korean
[기재정정]타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean stock market (DART system) regarding the 'Acquisition of Shares and Securities of Another Corporation' (타법인주식및출자증권취득결정). It details a correction to a previous filing concerning the acquisition of a subsidiary (CytoGen Japan). Since this is a specific corporate action announcement regarding investment and capital allocation that does not fit into the other specialized categories like M&A (which usually implies a merger or takeover of an existing entity) or Share Issue, it is best classified as a general Regulatory Filing (RNS).
2023-12-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.